Rituximab may not lead to increased infection rates in transplant recipients

American Journal of Transplantation

Volumn 10, Issue 12, 2010, Pages 2723-2724

  Drage, M ^a   Hadjianastassiou, V ^a   Dorling, A ^a   Mamode, N ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

RITUXIMAB; THYMOCYTE ANTIBODY;

BACTERIAL INFECTION; FOLLOW UP; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RATE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LETTER; LYMPHOMA; MYCOSIS; PRIORITY JOURNAL; VIRUS INFECTION;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFECTION; KIDNEY TRANSPLANTATION;

EID: 78649866498     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2010.03195.x     Document Type: Letter

References (5)

1. Kamar N, Milioto O, Puissant-Lubrano B,. Incidence and predictive factors for infectious disease after rituximab therapy in kidney transplant patients. Am J Transplant 2010; 10: 89-98.
2. Genberg H, Hansson A, Wernerson A, Wennberg L, Tyden G,. Pharmacodynamics of rituximab in kidney allotransplantation. Am J Transplant 2006; 6: 2418-2428.
3. Genberg H, Kumlien G, Wennberg L, Berg U, Tyden G,. ABO-incompatible kidney transplantation using antigen specific immunoabsorption and rituximab: A 3 year follow-up. Transplantation 2008; 85: 1745-1754.
4. Tyden G, Genberg H, Tollemar J, et al,. A randomized, double-blind, placebo-controlled, study of single dose rituximab as induction in renal transplantation. Transplantation 2009; 87: 1325-1329.
5. Harrell FE Jr, Lee KL, Matchar DB, Reichert TA,. Regression models for prognostic prediction: Advantages, problems, and suggested solutions. Cancer Treat Rep 1985; 69: 1071-1077.